Illumina 致力于支持推动遗传疾病认知不断发展的科研工作。Illumina 5-Base 解决方案通过在同一样本中同时进行遗传变异和 DNA 甲基化分析,实现基因组与表观基因组的整合分析。
Illumina 致力于支持推动遗传疾病认知不断发展的科研工作。Illumina 5-Base 解决方案通过在同一样本中同时进行遗传变异和 DNA 甲基化分析,实现基因组与表观基因组的整合分析。
Illumina 邀请符合条件的研究人员提交创新性的遗传疾病研究项目方案,利用 Illumina 5-Base 解决方案从同一样本中同时研究遗传变异和 DNA 甲基化。本科研资助项目旨在支持有助于深化遗传疾病研究中疾病机制、调控变异、复杂基因组发现以及甲基化相关生物学理解的研究。
本项目的主要目标包括:
本科研资助项目邀请符合条件的研究人员提交聚焦遗传疾病的研究方案,利用 Illumina 5-Base DNA Prep 试剂盒开展具有研究价值的课题。Illumina 5-Base 解决方案能够同步分析遗传变异和表观遗传变异,为解析遗传疾病机制提供统一的研究方法。
了解更多Illumina 5-base 解决方案
符合条件的申请者可提交一份约 400 字的摘要,阐述基于 Illumina 5-Base 解决方案开展的新研究项目。获资助项目将获得最多可支持 500 个样本检测所需的试剂盒及核心耗材。申请截止时间为太平洋标准时间(PST)2027 年 1 月 20 日晚 11:59。
获资助项目将从所有符合条件的申请中评选产生,评审工作由 Illumina 医学事务科学家和/或其他经批准的评审专家组成的评审委员会负责,并将依据以下标准对申请项目进行评估:
获资助项目将获得 5-Base DNA Prep 试剂盒及核心耗材,支持最多 500 个样本的研究需求。该资助旨在帮助研究人员利用 Illumina 5-Base 解决方案生成整合的基因组和表观基因组数据,用于遗传疾病研究。
获资助项目名单将于 2027 年 3 月 1 日公布。
申请开放时间: (ASHG 2026)2026 年 10 月 20 日
申请截止时间: 2027 年 1 月 20 日太平洋标准时间(PST)晚上 11:59
获资助项目公布时间: 2027 年 3 月 1 日
本科研资助项目面向符合条件、拟利用新一代测序(NGS)和 Illumina 5-Base 解决方案开展遗传疾病研究的研究人员。适合申请的研究项目包括发现性研究、转化研究或方法开发项目,这些项目需将整合的基因组与表观基因组分析应用于遗传疾病研究。
申请人可来自罕见病、神经发育性疾病、遗传性疾病、未确诊遗传疾病、复杂疾病或其他遗传疾病相关研究领域。完整资格要求请参阅正式条款与条件。
研究方向示例:
提交一份 400 字摘要,介绍拟利用 Illumina 5-Base 解决方案开展的遗传疾病研究项目。摘要应简明扼要,清晰说明研究目标、研究设计、拟使用的样本类型、预期分析方案,以及整合基因组与表观基因组分析可能带来的科学价值。
Illumina 科学家和管理团队组成的评审委员会将依据科学价值、创新性、可行性、潜在科学影响以及与 Illumina 价值观的一致性,对申请项目进行评审。
All grant submissions are confidential to the individual submitter and will not be published or distributed, provided, however, Illumina may share them with their own staff and distributors, who will not disclose them to third parties. Illumina may support the grant advertising efforts.
The winner will be selected by a panel of judges selected by Illumina. The panel may include representatives from Illumina. Upon project completion, the grant winner agrees to participate in at least one of the following activities relating to the specific project, with specific details of the applicable activity to be mutually agreed upon in good faith by Illumina and the winner: webinar, press release, case study, blog post, poster presentation, and/or conference presentation. The winner agrees that Illumina shall have the right to publicly announce the winner’s name and research title and use anonymized data from the winner's projects in application notes including in marketing materials and seminars—no public display of data will happen without prior consent from the winner.
Applicants must be 18 years of age or older and actively enrolled or employed at a research institution in a capacity in which they perform life science research and can process samples within six (6) months of award notification.
Applications must be:
By submitting a grant application, each applicant agrees that Illumina may use his or her name, abstract title, for marketing purposes.
Illumina or its affiliates may disclose the grant, including its terms, the identity of the winner, the nature of the relationship, the Prize (including it's monetary value), and any other transfers of value, in order to comply with applicable transparency laws and standards (e.g., Physician Payments Sunshine Act, Loi Bertrand, MedTech Europe, etc.).
All grant applicants agree that Illumina may process the personal data he or she provides as part of application, including sharing such data with Illumina’s partners, collaborators and other third parties who are obligated to keep the data confidential, and in accordance with Illumina’s privacy policies.
Applicants agree that Illumina may use applicant’s names, email addresses and affiliated institution to contact applicants for purposes of marketing of its products and services in accordance with the Illumina privacy policy here.
The grant award winner may be required to sign and return an affidavit of eligibility, release of liability, a publicity release, and other appropriate legal documentation reasonably requested by Illumina. No substitution or transfer of the awarded prize is allowed except as permitted by Illumina. The award winner is responsible for any local tax liability (city, state, or federal) occurred by winning and accepting the award. If, for any reason, the grant program may not run as planned for any causes beyond the reasonable control of Illumina, then Illumina reserves the right in its sole discretion to cancel, terminate, modify or suspend the grant program. These terms and conditions and any action related to this grant program will be governed by the laws of the State of California without regard to or application of its conflict of law provisions or your state or country of residence. All claims, legal proceedings or litigation arising in connection with these terms and conditions and this grant program will be brought solely in the federal or state courts located in San Diego County, California, and all applicants consent to the jurisdiction of and venue in such courts and waive any objection as to inconvenient forum. By participating in this grant program, each applicant unconditionally accepts and agrees to comply with and abide by these terms and conditions.
准备好提交申请了吗?请通过申请链接提交您的项目方案,包括 400 字项目摘要、相关补充材料及所需信息。所有申请材料须完整、原创,并于 2027 年 1 月 20 日前提交。
参与 Illumina 5-Base 解决方案科研资助项目,可为致力于推动遗传疾病研究发展的研究人员带来多方面价值。除获得资助的机会外,申请人还有机会提升个人学术影响力、拓展专业交流网络,并为未来申请其他科研资助项目奠定基础。
获资助项目将通过 Illumina 官网及社交媒体渠道获得重点展示。这不仅有助于提升研究人员的学术影响力,扩大研究成果的传播范围,也有助于提高业界对遗传疾病研究创新方法的关注。通过这些渠道展示研究项目,还有机会促进新的合作机会,吸引更广泛科研群体的关注,并进一步提升研究人员的专业影响力。
获资助者将受邀在 Illumina 主办的网络研讨会、学术论坛、访谈及/或其他相关活动中分享研究成果。这一平台可帮助研究人员与同行、技术专家及基因组学领域专家开展交流。通过参与相关活动,申请人有机会促进知识共享、拓展专业联系,并建立有助于未来科研发展的合作关系。
准备高质量申请材料的过程本身,也有助于争取机构支持,并为未来申请其他外部科研资助创造条件。与此同时,这一过程还可能帮助研究人员发现新的合作机会、优化研究假设,或挖掘进一步拓展研究方向的可能性。